Related Experiment Video

Updated: Dec 17, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.9K

Hypomethylating Agents in Lymphoma

Jacob C Cogan1, Yuxuan Liu1, Jennifer E Amengual2

  • 1Division of Hematology and Oncology, Columbia University Medical Center, William Black Building, 650 W 168th Street, Room 901, New York, NY, 10032, USA.

Current Treatment Options in Oncology
|July 1, 2020
PubMed
Abstract

Insights

Epigenetic mutations drive lymphoma development. Inhibitors targeting DNA and histone methylation show promise for treating these cancers, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Epigenetics
  • Hematology

Background:

  • Epigenetic mutations are common and pathogenic in specific lymphoma subtypes.
  • Germinal center-derived lymphomas (GC-DLBCL, FL, AITL) exhibit epigenetic dysregulation.
  • Current treatments need improvement, necessitating novel therapeutic strategies targeting disease pathogenesis.

Purpose of the Study:

  • To explore the therapeutic potential of epigenetic modulators in lymphoma treatment.
  • To investigate the role of DNA methyltransferase (DNMT) and EZH2 inhibitors in various lymphoma subtypes.
  • To highlight the emerging role of methyltransferase inhibitors in clinical practice for lymphoma.

Main Methods:

  • Review of existing literature on epigenetic alterations in lymphoma.
  • Analysis of studies investigating DNMT inhibitors for Diffuse Large B-cell Lymphoma (DLBCL) and T-cell Lymphoma (TCL).
  • Evaluation of EZH2 inhibitors' efficacy in relapsed/refractory Follicular Lymphoma (FL) with EZH2 mutations.

Main Results:

  • DNMT inhibitors are explored for enhancing chemotherapy response in DLBCL or as monotherapy/combination therapy in TCL.
  • Histone methyltransferase inhibitors show effectiveness in R/R FL patients with specific EZH2 mutations.
  • Histone deacetylase (HDAC) inhibitors have a long-standing clinical presence in lymphoma treatment.

Conclusions:

  • Epigenetic therapies, particularly methyltransferase inhibitors, are becoming increasingly important in lymphoma treatment.
  • Targeting epigenetic derangements offers a promising strategy for managing difficult-to-treat lymphomas.
  • New therapeutic options focusing on disease pathogenesis are crucial for improving patient outcomes.
Keywords:
Angioimmunoblastic T cell lymphoma (AITL)DNMT inhibitorDiffuse large B cell lymphoma (DLBCL)EZH2 inhibitorFollicular lymphoma (FL)Hypomethylating agents

More Related Videos

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.4K
Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution13:47

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution

Published on: February 24, 2015

26.0K

Related Concept Videos

Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
582
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
372
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
705